Humanized M195 monoclonal antibody conjugated to recombinant gelonin: An anti-CD33 immunotoxin with antileukemic activity

Clinical Cancer Research

Volumn 4, Issue 8, 1998, Pages 1971-1976

  Pagliaro, Lance C ^a,c   Liu, Baoshun ^a   Munker, Reinhold ^a   Andreeff, Michael ^a   Freireich, Emil J ^a   Scheinberg, David A ^b   Rosenblum, Michael G ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CD33 ANTIGEN; GELONIN; IMMUNOTOXIN; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HL 60; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE MARROW TRANSPLANTATION; CRYOPRESERVATION; HUMANS; IMMUNOTOXINS; LEUKEMIA, MYELOCYTIC, ACUTE; PLANT PROTEINS; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0031850006     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Vitetta, E. S., Stone, M., Amlot, P., Fay, J., May, R., Till, M., Newman, J., Clark, P., Collins, R., Cunningham, D., Ghetie, V., Uhr, J. W., and Thorpe, P. E. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res., 51: 4052-4058, 1991.
2. Amlot, P. L., Stone, M. J., Cunningham, D., Fay, J., Newman, J., Collins, R., May, M., McCarthy, M., Richardson, J., Ghetie, V., Ramilo, O., Thorpe, P. E., Uhr, J. W., and Vitetta, E. S. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood, 82: 2624-2633, 1993.
3. Amlot, P. L., Stone, M., Cunningham, D., Fay, J., Collins, R., Newman, J., Ghetie, V., Uhr, J. W., Vitetta, E., and Thorpe, P. Clinical experience with ricin immunotoxin. EACR-12: 12th Biennial Meeting of the European Association for Cancer Research, Brussels, Belgium, 1993.
4. LoBuglio, A. F., and Saleh, M. N. Advances in monoclonal antibody therapy of cancer. Am. J. Med. Sci., 304: 214-224, 1992.
5. Freeman, S. D., Kelm, S., Barber, E. K., and Crocker, P. R. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood, 85: 2005-2012, 1995.
6. Wagner, J. E., Collins, D., Fuller, S., Schain, L. R., Berson, A. E., Almici, C., Hall, M. A., Chen, K. E., Okarma, T. B., and Lebkowski, J. S. Isolation of small, primitive human hematopoietic stem cells: distribution of cell surface cytokine receptors and growth in SCID-Hu mice. Blood, 86: 512-523, 1995.
7. Schwartz, M. A., Lovett, D. R., Redner, A., Finn, R. D., Graham, M. C., Divgi, C. R., Dantis, L., Gee, T. S., Andreeff, M., Old, L. J., Larson, S. M., and Scheinberg, D. A. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J. Clin. Oncol., 11: 294-303, 1993.
8. Caron, P. C., Jurcic, J. G., Scott, A. M., Finn, R. D., Divgi, C. R., Graham, M. C., Jureidini, I. M., Sgouros, G., Tyson, D., Old, L. J., Larson, S. M., and Scheinberg, D. A. A phase IB trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood, 83: 1760-1768, 1994.
9. Co, M. S., Avdalovic, N. M., Caron, P. C., Avdalovic, M. V., Scheinberg, D. A., and Queen, C. Chimeric and humanized antibodies with specificity for the CD33 antigen. J. Immunol., 148: 1149-1154, 1991.
10. McGraw, K. J., Rosenblum, M. G., Cheung, L., and Scheinberg, D. A. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias. Cancer Immunol. Immunother., 39: 367-374, 1994.
11. Stirpe, F., Olsnes, S. E., and Pihl, A. Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. J. Biol. Chem., 255: 6947-6953, 1980.
12. Rosenblum, M. G., Kohr, W. A., Beatty, K. L., Beatty, W. G., Marks, W., Toman, P. D., and Cheung, L. Amino acid sequence analysis, gene construction, cloning, and expression of gelonin, a toxin derived from gelonium multiflorum. J. Interferon Cytokine Res., 15: 547-555, 1995.
13. Minden, M. D., Buick, R. N., and McCulloch, E. A. Separation of blast cell and T-lymphocyte progenitors in the blood of patients with acute myeloblastic leukemia. Blood, 54: 186-195, 1979.
14. Verdonek, L. F., Heesbeen, E. C., van Heugten, H. G., Staal, G. E. J., and Rijksen, G. The cytotoxicity of alkyl-lysophospholipid on clonogenic leukemia cells and on normal bone marrow progenitor cells is highly, but differentially, increased by cryopreservation. Bone Marrow Transplant., 9: 241-245, 1992.
15. Buick, R. N., Till, J. E., and McCulloch, E. A. Colony assay for proliferative blast cells circulating in myeloblastic leukaemia. Lancet, i: 186-863, 1977.
16. Rosenblum, M. G., Murray, J. L., Cheung, L., Rifkin, R., Salmon, S., and Bartholomew, R. A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin. Mol. Biother., 3: 6-13, 1991.
17. Tanimoto, M., Scheinberg, D. A., Cordon-Cardo, C., Huie, D., Clarkson, B. D., and Old, L. J. Restricted expression of an early myeloid and monocytic surface antigen defined by monoclonal antibody M195. Leukemia (Baltimore), 3: 339-348, 1989.
18. Raymakers, R., Wittebol, S., Pennings, A., Linders, E., Poddighe, P., and De Witte, T. Residual normal, highly proliferative progenitors can be isolated from the CD34+/33-fraction of AML with a more differentiated phenotype (CD33+). Leukemia (Baltimore), 9: 450-457, 1995.
19. Roy, D. C., Griffin, J. D., Belvin, M., Blattler, W. A., Lambert, J. M., and Ritz, J. Anti-MY9-blocked-ricin. An immunotoxin for selective targeting of acute myeloid leukemia cells. Blood, 77: 2404-2412, 1991.
20. Siegall, C. B., Gawlak, S. L., Chace, D., Wolff, E. A., Mixan, B., and Marquardt, H. Characterization of ribosome-inactivating proteins isolated from Bryonia dioica and their utility as carcinoma-reactive immunoconjugates. Bioconj. Chem., 5: 423-429, 1994.
21. Xu, Y., Xu, Q., Rosenblum, M. G., and Scheinberg, D. A. Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice. Leukemia (Baltimore), 10: 321-326, 1996.